Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82,051,282
-
Total 13F shares
-
86,940,196
-
Share change
-
+17,257,075
-
Total reported value
-
$1,978,662,987
-
Put/Call ratio
-
76%
-
Price per share
-
$22.75
-
Number of holders
-
165
-
Value change
-
+$415,131,771
-
Number of buys
-
106
-
Number of sells
-
56
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q3 2024
As of 30 Sep 2024,
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) was held by
165 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
86,940,196 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., VANGUARD GROUP INC, VR Adviser, LLC, Deep Track Capital, LP, Fairmount Funds Management LLC, Paradigm Biocapital Advisors LP, PERCEPTIVE ADVISORS LLC, COMMODORE CAPITAL LP, and Kynam Capital Management, LP.
This page lists
163
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.